McGowan Institute for Regenerative Medicine Awarded $12 Million Contract to Support Human Studies of Novel Treatments for Battlefield Injuries and Sca
PITTSBURGH, May 25 – A two-year, $12 million contract with the U.S. Department of Defense Office of Technology Transition (OTT) will jumpstart human trials of three innovative research programs that aim to replace scars and defects with healthy, functional tissues, announced officials of the University of Pittsburgh and the McGowan Institute for Regenerative Medicine today at the Institute’s Second Annual Open Session, Soldiers and Sailors Memorial Hall, Oakland. The OTT mission emphasizes the rapid translation of preclinical research into human studies to bring successful therapies